Batimastat sodium salt
(Synonyms: (2S,3R)-N-羟基-N'-[(2S)-1-甲基氨基-1-氧代-3-苯基丙-2-基]-3-异丁基-2-(噻吩-2-基硫甲基)丁二酰胺单钠盐,BB-94 sodium salt) 目录号 : GC35470A potent broad spectrum inhibitor of MMPs
Cas No.:130464-84-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Mice[5] Six-weeks-old female BALB/c mice are used. Mice are treated i.p. with Batimastat (BB-94, 50 mg/kg) 1 h before and 24 h post-infection. Batimastat is suspended at 50 mg/mL in DMSO and stored frozen at -20°C. Prior to use, it is diluted 20-fold in phosphate buffered saline (PBS), and 500 μL are injected into animals. Control mice are injected with 500 μL of 5% DMSO in PBS. Animals are sacrificed 48 h after i.c. challenge. Rats[6] Female Sprague-Dawley rats are administered a single physiological dose of E2 (40 μg/kg in a 0.9% NaCl, 0.4% EtOH vehicle) by intraperitoneal (i.p.) injection at the indicated time intervals prior to tissue collection at necropsy. This in vivo dose level of E2 has been shown to induce changes in uterine wet weight, tissue architecture, and gene expression characteristic of estrogen receptor activation. For all other experiments, animals are i.p. administered a single 40 μg/kg bolus of E2 4 h prior to tissue harvest, while control animals receive vehicle only in all studies. Batimastat is administered i.p. at a dose level (40 mg/kg in a 1× PBS, 0.1% Tween-20 vehicle) shown to be effective at inhibiting MMPs in vivo 4 h prior to E2 or saline control. |
References: [1]. Yin Z, et al. Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab. 2012 Jul 1;303(1):E55-70. |
Batimastat is a broad spectrum inhibitor of matrix metalloproteinases (MMP), with IC50 values of 1-5 nM for all MMPs tested, including MMP-1, -2, -3, -7, -9, -13, and -14.1,2,3,4 It also potently inhibits TNFα-converting enzyme (IC50 = 14.9 nM).2 Because of its action on MMPs, batimastat has anti-proliferative, anti-invasive, and anti-metastatic actions that are relevant, in particular, to cancer.5 Batimastat less effectively inhibits the processing of the low affinity IgE receptor CD23 (IC50 = 100 nM).6
1.Fray, M.J., Burslem, M.F., and Dickinson, R.P.Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chiralityBioorg. Med. Chem. Lett.11(4)567-570(2001) 2.Fray, M.J., Dickinson, R.P., Huggins, J.P., et al.A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcersJ. Med. Chem.46(16)3514-3525(2003) 3.Sheppard, G.S., Florjancic, A.S., Giesler, J.R., et al.Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsBioorg. Med. Chem. Lett.8(22)3251-3256(1998) 4.Yamamoto, M., Tsujishita, H., Hori, N., et al.Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocketJ. Med. Chem.41(8)1209-1217(1998) 5.Chaudhary, A.K., Pandya, S., Ghosh, K., et al.Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overviewMutat. Res.753(1)7-23(2013) 6.Bailey, S., Bolognese, B., Buckle, D.R., et al.Selective inhibition of low affinity IgE receptor (CD23) processingBioorg. Med. Chem. Lett.8(1)29-34(1998)
Cas No. | 130464-84-5 | SDF | |
别名 | (2S,3R)-N-羟基-N'-[(2S)-1-甲基氨基-1-氧代-3-苯基丙-2-基]-3-异丁基-2-(噻吩-2-基硫甲基)丁二酰胺单钠盐,BB-94 sodium salt | ||
Canonical SMILES | [O-]NC([C@@H](CSC1=CC=CS1)[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(NC)=O)=O)=O.[Na+] | ||
分子式 | C23H30N3NaO4S2 | 分子量 | 499.62 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0015 mL | 10.0076 mL | 20.0152 mL |
5 mM | 0.4003 mL | 2.0015 mL | 4.003 mL |
10 mM | 0.2002 mL | 1.0008 mL | 2.0015 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。